197 related articles for article (PubMed ID: 29680011)
1. Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement.
Klotz L; Shayegan B; Guillemette C; Collins LL; Gotto G; Guérette D; Jammal MP; Pickles T; Richard PO; Saad F
Can Urol Assoc J; 2018 Feb; 12(2):30-37. PubMed ID: 29680011
[TBL] [Abstract][Full Text] [Related]
2. Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer.
Klotz L; Breau RH; Collins LL; Gleave ME; Pickles T; Pouliot F; Saad F
Can Urol Assoc J; 2017; 11(1-2):16-23. PubMed ID: 28443139
[TBL] [Abstract][Full Text] [Related]
3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
4. Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
Tremblay S; Summers-Trasiewicz L; Pouliot F; Crook JM; Ding K; Klotz L; Toren P
J Urol; 2021 Nov; 206(5):1166-1176. PubMed ID: 34184929
[TBL] [Abstract][Full Text] [Related]
5. Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.
Shayegan B; Pouliot F; So A; Fernandes J; Macri J
Can Urol Assoc J; 2017 Jun; 11(6):204-209. PubMed ID: 28652880
[TBL] [Abstract][Full Text] [Related]
6. LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion.
de Jong IJ; Eaton A; Bladou F
Curr Med Res Opin; 2007 May; 23(5):1077-80. PubMed ID: 17519074
[TBL] [Abstract][Full Text] [Related]
7. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
Nishiyama T
Urol Oncol; 2014 Jan; 32(1):38.e17-28. PubMed ID: 23769268
[TBL] [Abstract][Full Text] [Related]
8. The Relationship between Hot Flashes and Testosterone Recovery after 12 Months of Androgen Suppression for Men with Localised Prostate Cancer in the ASCENDE-RT Trial.
Dosani M; Morris WJ; Tyldesley S; Pickles T
Clin Oncol (R Coll Radiol); 2017 Oct; 29(10):696-701. PubMed ID: 28712786
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.
Shore ND; Antonarakis ES; Cookson MS; Crawford ED; Morgans AK; Albala DM; Hafron J; Harris RG; Saltzstein D; Brown GA; Henderson J; Lowentritt B; Spier JM; Concepcion R
Prostate; 2020 May; 80(6):527-544. PubMed ID: 32130741
[TBL] [Abstract][Full Text] [Related]
10. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
11. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Mostaghel EA; Page ST; Lin DW; Fazli L; Coleman IM; True LD; Knudsen B; Hess DL; Nelson CC; Matsumoto AM; Bremner WJ; Gleave ME; Nelson PS
Cancer Res; 2007 May; 67(10):5033-41. PubMed ID: 17510436
[TBL] [Abstract][Full Text] [Related]
12. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
[TBL] [Abstract][Full Text] [Related]
14. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
Atkins KM; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
Cancer; 2018 Apr; 124(7):1383-1390. PubMed ID: 29266181
[TBL] [Abstract][Full Text] [Related]
15. Androgen metabolic pathway involved in current and emerging treatment for men with castration resistant prostate cancer: intraprostatic androgens as therapeutic targets and endocrinological biomarkers.
Hara N; Nishiyama T
Curr Drug Targets; 2014; 15(13):1215-24. PubMed ID: 25341420
[TBL] [Abstract][Full Text] [Related]
16. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
Wang Y; Dai B; Ye DW
Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
[TBL] [Abstract][Full Text] [Related]
17. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
18. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
[TBL] [Abstract][Full Text] [Related]
19. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
[TBL] [Abstract][Full Text] [Related]
20. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF
Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]